Central Nervous System (CNS) Therapeutics Market By Drug Class (Small Molecule Drugs, Biologics and Advanced Therapies); By Indication (Neurodegenerative Diseases, Psychiatric Disorders, Epilepsy and Seizure Disorders, Multiple Sclerosis, Pain Management and Neuropathic Pain); By Route of Administration (Oral, Injectable, Transdermal/Others); By End User (Hospitals & Specialty Clinics, Retail & Online Pharmacies, Research & Academic Institutes, Mental Health Centers, Military & Veteran Health Systems); By Geography, Segment Revenue Estimation, Forecast, 2024–2030.

Introduction And Strategic Context

The Global Central Nervous System (CNS) Therapeutics Market will witness a robust CAGR of 8.6 % , valued at USD 138.2 billion in 2024, expected to appreciate and reach USD 226.7 billion by 2030, confirms Strategic Market Research. The market encompasses pharmaceutical and biologic treatments targeting diseases and disorders that affect the brain, spinal cord, and peripheral nerves—including conditions like multiple sclerosis, epilepsy, Alzheimer’s disease, Parkinson’s disease, depression, schizophrenia, and neuropathic pain.

 

This market stands at a pivotal juncture due to the growing global burden of neurological and psychiatric disorders. As populations age, the prevalence of neurodegenerative diseases such as Alzheimer’s and Parkinson’s continues to surge, while mental health disorders, exacerbated by pandemic-era stressors and modern lifestyle factors, demand greater therapeutic attention. Furthermore, advances in neuroimaging, biomarkers, and precision medicine are transforming diagnosis and treatment, opening new revenue streams for pharmaceutical innovators.

 

From a regulatory standpoint, global agencies such as the FDA and EMA are increasingly offering expedited pathways—including Breakthrough Therapy Designation and Orphan Drug Status—to accelerate drug development for CNS indications with high unmet need. However, the CNS drug pipeline remains challenging due to high R&D attrition rates, complex clinical trial designs, and difficulties in demonstrating efficacy for disorders with subjective endpoints.

 

On the investment horizon, significant venture capital and pharma partnerships are being directed toward innovative modalities like gene therapy, RNA-based drugs, monoclonal antibodies, and neuromodulation devices aimed at CNS disorders. Moreover, digital therapeutics are emerging as adjunctive treatments, particularly in psychiatric care, fueling a blended therapeutic landscape that integrates pharmacological and digital approaches.

 

Key stakeholders in the CNS therapeutics market include pharmaceutical and biotechnology companies , academic research institutions , contract research organizations (CROs) , healthcare providers , insurance payers , and regulatory authorities . Investors and private equity players are increasingly viewing CNS as a high-risk but potentially high-reward segment, given the commercial success of blockbuster drugs in neurology and psychiatry.

 

Experts note that while CNS R&D remains among the riskiest therapeutic frontiers, even incremental breakthroughs can generate significant market returns due to the chronic nature of these disorders and the lack of curative treatments. The rising tide of patient advocacy and growing public awareness is pushing governments and global health bodies to prioritize mental health and neurological care in future healthcare policies.

 

Market Segmentation And Forecast Scope

The central nervous system (CNS) therapeutics market is broadly segmented based on Drug Class , Indication , Route of Administration , End User , and Region . These segmentation dimensions reflect the diverse therapeutic landscape, regulatory pathways, and evolving treatment paradigms across neurology and psychiatry.

By Drug Class

• Small Molecule Drugs These remain the backbone of CNS therapeutics, accounting for an estimated 72.4% share of global revenue in 2024. They include traditional chemical drugs for depression, epilepsy, and neurodegenerative diseases. Their dominance stems from oral bioavailability, generic availability, and lower production costs.

• Biologics and Advanced Therapies Representing a rapidly growing segment, biologics—including monoclonal antibodies, gene therapies, and RNA-based treatments—are gaining momentum in areas like multiple sclerosis and rare neurological disorders. This segment is anticipated to be the fastest-growing drug class with a CAGR exceeding 10.3% from 2024 to 2030. Industry experts foresee biologics capturing a much higher revenue share post-2028, driven by breakthrough approvals and pricing premiums.

 

By Indication

• Neurodegenerative Diseases Covers Alzheimer’s, Parkinson’s, ALS, Huntington’s disease, etc. Rising elderly populations and significant unmet need for disease-modifying therapies drive this segment.

• Psychiatric Disorders Includes depression, schizophrenia, bipolar disorder, anxiety disorders, and others. Mental health awareness and digital health integration support ongoing growth.

• Epilepsy and Seizure Disorders Represents a mature yet stable segment, sustained by new drug launches offering better safety profiles.

• Multiple Sclerosis (MS) One of the highest-value segments in the CNS therapeutics market, fueled by biologics and oral disease-modifying therapies.

• Pain Management and Neuropathic Pain Neuropathic pain remains a significant sub-segment given the opioid crisis and demand for non-addictive alternatives.

Among indications, neurodegenerative diseases are poised to be the most strategic growth area due to breakthrough R&D and regulatory incentives for disease-modifying therapies.

 

By Route of Administration

• Oral Dominates patient preference due to convenience and compliance.

• Injectable Biologics and advanced therapies drive growth in injectable formulations, particularly for MS and rare CNS disorders.

• Transdermal / Others Niche but growing for drugs requiring steady plasma levels or avoiding first-pass metabolism.

 

By End User

• Hospitals & Specialty Clinics Account for the majority of biologic therapy administration and complex neurological care.

• Retail & Online Pharmacies Key channels for chronic medications, including antidepressants and antiepileptics.

• Research & Academic Institutes Critical stakeholders in early-stage CNS R&D and clinical trials.

 

By Region

• North America Largest market, driven by high healthcare expenditure, rapid biologic uptake, and supportive regulatory frameworks.

• Europe Strong adoption of innovative therapies and significant government support for neurological disease research.

• Asia Pacific Fastest-growing region due to rising disease prevalence, expanding healthcare access, and increasing mental health awareness.

• Latin America, Middle East & Africa (LAMEA) Emerging markets with growing investment interest but remain price-sensitive and underserved in specialty therapeutics.

 

Market Trends And Innovation Landscape

The central nervous system (CNS) therapeutics market is experiencing a transformative era, shaped by scientific advances, digital convergence, and shifting regulatory priorities. From traditional small-molecule drugs to cutting-edge biologics and digital solutions, the innovation landscape in CNS therapeutics is both intensely competitive and brimming with opportunities.

Rise of Disease-Modifying Therapies

Historically, CNS drugs were primarily symptomatic treatments, offering relief rather than halting disease progression. However, the tide is turning:

• Alzheimer’s Disease: Recent approvals of amyloid-targeting monoclonal antibodies, albeit controversial, have sparked renewed R&D enthusiasm. Despite mixed efficacy data, these developments have opened regulatory pathways for other mechanisms like tau inhibitors and neuroinflammation modulators.

• Parkinson’s Disease: Gene therapy candidates are advancing in clinical trials, aiming to restore dopamine synthesis directly in affected brain regions.

• Multiple Sclerosis (MS): The market has shifted dramatically from injectables to high-efficacy oral agents and monoclonal antibodies. Experts believe that the competitive pipeline in MS is a precursor to broader trends across neurodegeneration, where targeted immunomodulation is taking center stage.

 

Innovation in Drug Modalities

• Monoclonal Antibodies ( mAbs ): Once confined to oncology, mAbs are now pivotal in neurology, exemplified by drugs targeting migraine (CGRP inhibitors) and autoimmune neuroinflammation.

• Gene Therapies and RNA-Based Drugs: Promising candidates for rare CNS disorders such as spinal muscular atrophy (SMA), Huntington’s disease, and inherited neuropathies are gaining regulatory momentum, driven by Orphan Drug incentives.

• Digital Therapeutics: Particularly in psychiatry, digital platforms are emerging as standalone or adjunctive treatments for conditions like depression, anxiety, and ADHD. These solutions integrate behavioral therapy, cognitive exercises, and real-time patient monitoring.

Industry analysts predict that the future CNS treatment landscape will involve multi-modal regimens blending pharmacological, digital, and possibly neuromodulation interventions for holistic patient management.

 

Challenges in CNS Drug Development

Despite progress, CNS remains among the highest-risk therapeutic areas in pharma R&D:

• Blood-Brain Barrier (BBB): Limits drug penetration and restricts therapeutic targets. New technologies, including nanoparticle carriers and focused ultrasound, are being explored to enhance BBB permeability.

• Subjective Endpoints: Psychiatric drug trials suffer high placebo responses and inconsistent outcome measures, prolonging trial durations and complicating approvals.

• High Attrition Rates: CNS pipelines carry some of the industry’s highest late-stage failure rates, deterring investment in riskier indications without clear biomarkers.

One neuroscientist notes , “We’re pushing the limits of science in the brain. The biology is immensely complex, but even incremental efficacy can mean billions in commercial value, given the size of these patient populations and unmet needs.”

 

Pipeline Momentum and Partnerships

Recent years have witnessed strong pipeline momentum:

• Numerous collaborations between large pharma and biotech firms aim to co-develop novel CNS therapies, pooling R&D costs and sharing regulatory risk.

• Big tech firms are entering digital mental health, forging partnerships with pharmaceutical companies to blend apps with drug therapy.

• Venture capital investment in neuro startups surged post-2020, with mental health and neurodegeneration attracting significant funding rounds.

 

Regulatory and Reimbursement Evolution

Regulatory agencies are adapting:

• FDA’s Accelerated Approval Pathways are increasingly utilized for neurodegenerative diseases despite controversies about surrogate endpoints.

• In Europe, EMA and national HTA bodies are cautiously receptive to paying premium prices for therapies demonstrating even modest efficacy in high-burden conditions.

Market watchers highlight that payers remain cautious and demand robust real-world evidence before committing to reimburse high-cost CNS therapies, especially in indications with subjective clinical benefit.

 

Competitive Intelligence And Benchmarking

The central nervous system (CNS) therapeutics market is characterized by a diverse competitive landscape comprising global pharmaceutical giants, specialized biotech innovators, and emerging digital therapeutics companies. The competitive environment is defined by high R&D intensity, strategic M&A activity, and the constant pursuit of differentiation in a market fraught with scientific and regulatory hurdles.

1. Biogen

• Strategy: Biogen is renowned for its leadership in neurodegenerative diseases, notably multiple sclerosis and Alzheimer’s disease . Its pipeline strategy focuses on disease-modifying therapies, including monoclonal antibodies and novel modalities targeting neuroinflammation and tau pathology.

• Global/Regional Reach: Operates globally, with a significant presence in North America, Europe, and key Asian markets.

• Differentiation: Biogen’s willingness to pursue high-risk, high-reward projects has positioned it as both a pioneer and a lightning rod for regulatory debate, particularly after the contentious launch of its Alzheimer’s monoclonal antibody.

 

2. Eli Lilly and Company

• Strategy: Eli Lilly has doubled down on CNS therapeutics, especially Alzheimer’s disease , with several amyloid and tau-targeting agents in advanced development. The company also maintains a significant portfolio in psychiatric disorders.

• Global/Regional Reach: Strong global footprint, with significant revenue in the U.S. and Europe, expanding aggressively in Asia-Pacific.

• Differentiation: Lilly is pursuing parallel development of digital solutions to complement pharmacological treatments, signaling its vision for integrated mental health care.

 

3. Johnson & Johnson (Janssen Pharmaceuticals)

• Strategy: Active in both neurology and psychiatry, J&J focuses on schizophrenia, mood disorders, epilepsy, and neurodegenerative diseases. Their pipeline spans small molecules, biologics, and long-acting injectables.

• Global/Regional Reach: Present in over 150 countries, leveraging deep commercial infrastructure.

• Differentiation: Janssen’s strategic emphasis on long-acting injectables in psychiatry offers significant competitive advantage in improving patient adherence and outcomes.

 

4. Roche

• Strategy: Roche continues to invest in neuroscience with assets in multiple sclerosis , rare neurogenetic diseases, and Alzheimer’s disease. Its approach combines biologics, biomarkers, and advanced diagnostics.

• Global/Regional Reach: Strong in Europe, North America, and emerging markets.

• Differentiation: Roche’s integration of therapeutic and diagnostic innovation gives it a unique edge in personalizing CNS treatments and identifying responsive patient subgroups.

 

5. Novartis

• Strategy: Novartis is a major player in multiple sclerosis , leveraging both small molecules and monoclonal antibodies. The firm is also active in gene therapies for rare neurological disorders.

• Global/Regional Reach: Extensive global presence, with aggressive expansion in Asia-Pacific and Latin America.

• Differentiation: Novartis is noted for pushing boundaries in advanced therapies, including gene therapies that aim to address root causes of CNS disorders rather than merely symptoms.

 

6. Pfizer

• Strategy: While Pfizer had historically reduced its CNS footprint, it has recently re-entered the space with partnerships and in-licensing deals, particularly focused on neurology and rare diseases.

• Global/Regional Reach: Operates globally, with strategic alliances enhancing its CNS presence.

• Differentiation: Pfizer’s renewed interest in CNS reflects a broader industry trend of seeking high-value niches with significant unmet need.

 

7. Lundbeck

• Strategy: As a CNS-focused specialty company, Lundbeck’s portfolio is anchored in psychiatry and neurology, including depression, schizophrenia, Alzheimer’s, and Parkinson’s. The company emphasizes innovative mechanisms of action to differentiate in crowded markets.

• Global/Regional Reach: Strong European base with expansion in North America and Asia.

• Differentiation: Lundbeck’s single-minded CNS focus enables specialized expertise and nimbleness compared to diversified pharma giants.

 

Competitive Dynamics:

• Intense rivalry in multiple sclerosis and Alzheimer’s disease , where several biologics are vying for regulatory approvals and market share.

• Digital therapeutics startups are partnering with big pharma, seeking synergistic models combining pharmacotherapy and digital interventions, especially in psychiatric disorders.

• M&A activity remains robust as large pharmaceutical companies seek to acquire promising pipelines to bolster growth amid looming patent expirations.

• Pricing pressures and demands for real-world evidence increasingly dictate competitive strategy, particularly in high-cost biologics.

Industry observers highlight that the CNS space remains one of the highest risk-reward areas in pharma, where scientific breakthroughs can yield blockbuster revenues—but failures can swiftly erode billions in market value.

 

Regional Landscape And Adoption Outlook

The central nervous system (CNS) therapeutics market exhibits distinct regional dynamics, shaped by differences in disease prevalence, healthcare infrastructure, reimbursement environments, and regulatory frameworks. Each region offers unique opportunities and challenges for stakeholders aiming to commercialize CNS therapies.

North America

• Market Size & Growth: Dominates the global CNS therapeutics market, accounting for an estimated 43–47% of global revenues in 2024.

• Drivers: High prevalence of neurodegenerative and psychiatric disorders, early adoption of biologics, and advanced healthcare systems sustain market leadership. The United States benefits from expedited regulatory pathways, such as FDA’s Breakthrough Therapy Designation, enabling faster drug launches.

• Challenges: Despite innovation, cost pressures and debates around drug pricing, especially for Alzheimer’s therapies, create reimbursement hurdles.

• White Space: Rural and underserved communities with limited access to specialist neurological care.

• Key Countries: United States, Canada

Experts note that North America’s robust reimbursement environment for innovative CNS drugs offers strong commercial prospects, but manufacturers must prepare for intense scrutiny over clinical value and cost-effectiveness.

 

Europe

• Market Size & Growth: Represents the second-largest regional market, with steady growth fueled by aging demographics and increasing mental health awareness.

• Drivers: Strong emphasis on neurological research funding and relatively swift market access for innovative therapies in Western Europe. HTA bodies, however, enforce stringent cost-effectiveness criteria, influencing market uptake.

• Challenges: Variation in reimbursement timelines between countries, slowing access in some regions despite EMA approvals.

• White Space: Eastern Europe remains less penetrated, offering opportunity for generic CNS drugs and affordable biologic biosimilars.

• Key Countries: Germany, UK, France, Italy, Spain

European neurologists emphasize that payer pressure is reshaping market dynamics, prompting companies to generate high-quality real-world evidence alongside pivotal trials.

 

Asia Pacific

• Market Size & Growth: The fastest-growing regional market, with a projected CAGR exceeding 8.9% from 2024 to 2030.

• Drivers: Rising incidence of neurodegenerative and psychiatric disorders, expanding middle-class healthcare spending, and government initiatives to improve mental health services. Rapid urbanization and stress-related psychiatric conditions also contribute to demand growth.

• Challenges: High out-of-pocket spending limits patient access to expensive biologics. Regulatory systems vary widely, impacting drug approval timelines.

• White Space: Rural areas with low awareness and diagnosis rates for CNS conditions. Potential growth in digital therapeutics as smartphone penetration expands.

• Key Countries: China, Japan, India, South Korea, Australia

Industry insiders highlight Asia Pacific as a critical strategic focus for CNS drug developers, given the region’s sheer population and rising healthcare investments.

 

Latin America, Middle East & Africa (LAMEA)

• Market Size & Growth: Represents a smaller portion of global revenues but offers significant long-term potential.

• Drivers: Improving healthcare infrastructure, rising awareness of mental health, and increased government focus on non-communicable diseases.

• Challenges: Price sensitivity, lower healthcare budgets, and fragmented healthcare systems hamper rapid uptake of innovative CNS therapies.

• White Space: Largely untapped markets for generic CNS drugs, as well as opportunities for cost-effective digital therapeutics to improve mental health support in resource-limited settings.

• Key Countries: Brazil, Saudi Arabia, South Africa, Argentina

Experts observe that while multinational pharma companies are cautiously expanding in LAMEA, affordability remains a primary concern, necessitating tailored commercial models.

 

Regional Adoption Insights:

• Adoption of high-cost biologics remains most concentrated in North America and Western Europe , where reimbursement mechanisms can accommodate expensive therapies.

• Asia Pacific is becoming a priority for new launches, though affordability challenges persist for advanced therapies.

• Emerging markets show strong demand for generic CNS drugs and cost-effective treatments, creating white space opportunities for regional and multinational players alike.

Analysts emphasize that future CNS market growth will hinge on navigating regional disparities in regulation, payer dynamics, and patient access, demanding highly localized strategies from global pharmaceutical firms.

 

End-User Dynamics And Use Case

The central nervous system (CNS) therapeutics market serves a complex ecosystem of end users whose needs vary dramatically depending on disease severity, treatment modality, and healthcare infrastructure. Understanding these dynamics is crucial for market players aiming to optimize commercialization strategies and enhance patient outcomes.

Hospitals & Specialty Clinics

• Role: Primary hubs for managing severe neurological and psychiatric conditions requiring specialist intervention, diagnostics, and administration of biologic therapies.

• Adoption Drivers: Access to advanced diagnostic tools (e.g., neuroimaging, biomarker assays), presence of neurologists and psychiatrists, and capacity to manage infusion-based treatments.

• Challenges: High cost of biologic therapies strains hospital budgets, necessitating negotiations with payers for reimbursement.

Experts note that hospitals are increasingly critical for biologics, gene therapies, and rare disease treatments where complex handling and monitoring are required.

 

Retail & Online Pharmacies

• Role: Handle the bulk of dispensing for chronic oral CNS therapies such as antidepressants, antiepileptics, and anxiolytics.

• Adoption Drivers: Convenience, increasing patient preference for home delivery services, and strong generic penetration lowering costs for consumers.

• Challenges: Regulatory scrutiny regarding controlled substances in psychiatric care; concerns about medication adherence without clinical oversight.

The growing trend toward e-pharmacies, particularly in Asia-Pacific, signals a shift in how patients access maintenance medications for CNS disorders.

 

Research & Academic Institutes

• Role: Pivotal in early-stage drug discovery, preclinical models, and running complex clinical trials in CNS diseases. Academic centers often serve as key opinion leader (KOL) hubs influencing clinical practice patterns.

• Adoption Drivers: Funding from government grants and private foundations targeting neurological research; collaborations with pharma for pipeline development.

• Challenges: Limited resources for large-scale trials; high dependence on external funding.

 

Mental Health Centers & Community Health Facilities

• Role: Frontline facilities managing psychiatric disorders, particularly mild-to-moderate cases of depression, anxiety, and schizophrenia.

• Adoption Drivers: Expansion of mental health programs and government funding to reduce stigma and improve access to care.

• Challenges: Workforce shortages, high patient volumes, and limited budgets impede widespread adoption of advanced therapies.

 

Military & Veteran Health Systems

• Role: Specialized segment dealing with high prevalence of PTSD, traumatic brain injury (TBI), and other CNS conditions among service members and veterans.

• Adoption Drivers: Government support, dedicated funding, and unique patient populations with specific neurological and psychiatric needs.

• Challenges: Bureaucratic procurement processes and stringent evidence requirements for new therapies.

 

USE CASE

Consider the following real-world scenario highlighting how CNS therapeutics can transform patient care:

A tertiary hospital in South Korea recently adopted a new monoclonal antibody therapy for early-stage Alzheimer’s disease . A 68-year-old patient exhibiting mild cognitive impairment underwent advanced PET imaging confirming amyloid-beta accumulation. The hospital’s neurology team initiated monthly infusions of the biologic treatment, carefully monitoring for amyloid-related imaging abnormalities (ARIA).

Over the next 12 months, cognitive assessments revealed stabilization of memory decline, allowing the patient to continue daily activities independently. While side effects, including transient brain swelling, were observed in some patients, careful screening protocols and MRI monitoring enabled safe continuation of therapy.

This case underscores how biologic innovations, coupled with advanced diagnostics and specialized care, are shifting the paradigm from symptomatic management to disease-modifying strategies in CNS disorders.

Industry experts emphasize that such integrated treatment models will increasingly define CNS therapeutics, blending precision diagnostics, biologics, and vigilant monitoring to achieve improved patient outcomes.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

The CNS therapeutics market has seen significant activity, reflecting a high level of innovation and strategic maneuvering among major players:

• FDA Approval of New Alzheimer’s Therapies (2024): The FDA approved a monoclonal antibody targeting amyloid-beta plaques in early Alzheimer’s disease, triggering debate over clinical benefits, cost, and real-world effectiveness. The approval has ignited further investment into disease-modifying approaches. FDA News Release

• Biogen and Eisai Collaboration Expansion (2024): Biogen and Eisai announced extended partnerships for developing additional neurodegeneration therapies, focusing on tau pathology and neuroinflammation mechanisms. Biogen Newsroom

• Digital Therapeutics Gaining Momentum (2025): Digital solutions for depression and anxiety received regulatory clearance in both the U.S. and Europe, reflecting growing acceptance of non-pharmacologic interventions in mental health care. Digital Therapeutics Alliance

• Novartis Advances Gene Therapy Pipeline (2025): Novartis reported positive Phase II data for an investigational gene therapy in Huntington’s disease, signaling progress toward addressing previously untreatable neurogenetic conditions. Novartis Media Releases

• Venture Funding Surge in Neuro Startups (2024-2025): Neuro-focused biotech startups collectively raised over $2 billion across various funding rounds, particularly in rare diseases and psychiatric care. Crunchbase News

 

Opportunities

• Emerging Markets and Asia Pacific Growth: Rapid economic growth, increasing neurological disease prevalence, and expanding healthcare coverage in Asia Pacific create fertile ground for market expansion.

• Digital Integration in Psychiatric Care: The rise of digital therapeutics offers pharmaceutical companies opportunities to create hybrid treatment models, improving patient adherence and outcomes, particularly in mental health.

• Precision Medicine and Biomarker Development: Progress in neuroimaging and fluid biomarkers enables better patient stratification, paving the way for more successful clinical trials and personalized therapies. Experts predict that the ability to target subpopulations in neurodegenerative diseases will be a game changer, reducing the high failure rates that have historically plagued CNS drug development.

 

Restraints

• High R&D Attrition Rates: CNS drug development remains one of the riskiest therapeutic areas, with high late-stage clinical trial failure rates due to complex disease biology and subjective efficacy endpoints.

• Affordability and Reimbursement Challenges: Expensive biologic therapies for CNS conditions face payer pushback, particularly in Alzheimer’s and rare diseases where long-term outcomes remain uncertain. Analysts caution that without clear evidence of cost-effectiveness, market uptake may be restricted despite regulatory approvals.

Industry thought leaders assert that while the CNS therapeutics market is a high-risk arena, the immense commercial potential and societal need ensure continued investment and innovation.
 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 138.2 Billion
Revenue Forecast in 2030	USD 226.7` Billion
Overall Growth Rate	CAGR of 8.6% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Drug Class, By Indication, By Route of Administration, By End User, By Geography
By Drug Class	Small Molecule Drugs, Biologics and Advanced Therapies
By Indication	Neurodegenerative Diseases, Psychiatric Disorders, Epilepsy and Seizure Disorders, Multiple Sclerosis, Pain Management and Neuropathic Pain
By Route of Administration	Oral, Injectable, Transdermal/Others
By End User	Hospitals & Specialty Clinics, Retail & Online Pharmacies, Research & Academic Institutes, Mental Health Centers, Military & Veteran Health Systems
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, China, India, Japan, Brazil, etc.
Market Drivers	- Growing burden of neurodegenerative and psychiatric disorders - Advances in biologics and gene therapies - Rising investment in digital therapeutics
Customization Option	Available upon request